drugset / Trial / NCT00006048

ZD 1839 Plus Combination Chemotherapy in Treating Patients With Non-Small Cell Lung Cancer

NCT00006048

Phase 3 Unknown AstraZeneca
Treatment

Summary

RATIONALE: Some tumors need growth factors produced by the body's white blood cells to keep growing. ZD 1839 may interfere with the growth factor and stop the tumor from growing. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not yet known whether chemotherapy is more effective with or without ZD 1839 for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without ZD 1839 in treating patients who have stage IIIB or stage IV non-small cell lung cancer.

Timeline

Start
2000-05
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Gefitinib Small molecule Oral
Background Cisplatin Other / unclassified
Background Gemcitabine Small molecule

Indications